曲妥珠单抗-德鲁替康改善 HER2 阳性转移性乳腺癌和脑转移患者的无进展生存期和颅内应答。
Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases.
出版信息
Oncologist. 2022 Mar 28;27(Suppl 1):S3-S4. doi: 10.1093/oncolo/oyac009.
Abstract
In the phase III DESTINY-Breast03 trial, trastuzumab deruxtecan improved progression-free survival (PFS) relative to trastuzumab emtansine across all patients with HER2-positive metastatic breast cancer, including a 75% improvement in PFS among those with baseline brain metastases.
摘要
在 III 期 DESTINY-Breast03 试验中，与曲妥珠单抗恩美曲妥珠单抗相比，曲妥珠单抗 deruxtecan 改善了所有 HER2 阳性转移性乳腺癌患者的无进展生存期 (PFS)，包括基线时有脑转移的患者的 PFS 改善了 75%。
相似文献
1
Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases.曲妥珠单抗-德鲁替康改善 HER2 阳性转移性乳腺癌和脑转移患者的无进展生存期和颅内应答。
Oncologist. 2022 Mar 28;27(Suppl 1):S3-S4. doi: 10.1093/oncolo/oyac009.
2
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新用于乳腺癌。
N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
3
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
4
Trastuzumab deruxtecan for HER2+ advanced breast cancer.曲妥珠单抗-德曲妥珠单抗用于治疗 HER2 阳性晚期乳腺癌。
Future Oncol. 2022 Jan;18(1):7-19. doi: 10.2217/fon-2021-0550. Epub 2021 Nov 26.
5
HER2-positive metastatic breast cancer: a comprehensive review.人表皮生长因子受体 2 阳性转移性乳腺癌：全面综述。
Clin Adv Hematol Oncol. 2021 Jan;19(1):40-50.
6
Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy.在基于图卡替尼的治疗失败后，接受曲妥珠单抗-德曲妥珠单抗治疗的HER2扩增型乳腺癌患者脑转移的颅内反应。
Eur J Cancer. 2023 Jul;187:161-163. doi: 10.1016/j.ejca.2023.03.030. Epub 2023 May 9.
7
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康治疗 HER2 阳性乳腺癌伴脑转移：一项单臂、2 期临床试验。
Nat Med. 2022 Sep;28(9):1840-1847. doi: 10.1038/s41591-022-01935-8. Epub 2022 Aug 8.
8
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis.曲妥珠单抗 deruxtecan 治疗人表皮生长因子受体 2 阳性乳腺癌脑转移瘤：系统评价和荟萃分析。
ESMO Open. 2024 Feb;9(2):102233. doi: 10.1016/j.esmoop.2024.102233. Epub 2024 Feb 5.
9
Trastuzumab Deruxtecan Is Effective in HER2-Low Breast Cancer.曲妥珠单抗-德鲁替康在 HER2 低表达乳腺癌中有效。
Cancer Discov. 2020 Apr;10(4):488. doi: 10.1158/2159-8290.CD-RW2020-030. Epub 2020 Feb 28.
10
Brain Metastasis from HER2-Positive Breast Cancer: An Evolving Landscape.HER2阳性乳腺癌的脑转移：不断演变的格局
Clin Cancer Res. 2023 Jan 4;29(1):8-10. doi: 10.1158/1078-0432.CCR-22-2853.
引用本文的文献
1
HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities.非小细胞肺癌（NSCLC）中的HER2改变：从生物学、检测到治疗方式的进展
Front Oncol. 2025 Jun 20;15:1624124. doi: 10.3389/fonc.2025.1624124. eCollection 2025.
2
Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy.曲妥珠单抗德鲁昔单抗在基于吡咯替尼的治疗失败后的HER2阳性脑转移乳腺癌患者中的疗效和安全性。
Sci Rep. 2025 May 22;15(1):17731. doi: 10.1038/s41598-025-02550-6.
3
Metastatic brain tumors: from development to cutting-edge treatment.转移性脑肿瘤：从发展到前沿治疗
MedComm (2020). 2024 Dec 20;6(1):e70020. doi: 10.1002/mco2.70020. eCollection 2025 Jan.
4
Case report: Efficacy of later-line fam-trastuzumab deruxtecan in a patient with triple-positive breast cancer with brain metastases.病例报告：二线曲妥珠单抗德鲁昔单抗治疗三阳性乳腺癌脑转移患者的疗效
Front Oncol. 2024 Nov 4;14:1470560. doi: 10.3389/fonc.2024.1470560. eCollection 2024.
5
Overview on Current Trends and Emerging Therapies in the Chemotherapy of Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.人表皮生长因子受体2阳性乳腺癌患者化疗的当前趋势与新兴疗法概述
Galen Med J. 2023 Aug 20;12:e3021. doi: 10.31661/gmj.v12i0.3021. eCollection 2023.
6
Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer.乳腺癌中抗HER2抗体药物偶联物的作用机制及耐药性
Cancer Drug Resist. 2024 Jun 3;7:22. doi: 10.20517/cdr.2024.06. eCollection 2024.
7
HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies.HER2改变的非小细胞肺癌：从当前方法到新兴策略的历程
Cancers (Basel). 2024 May 26;16(11):2018. doi: 10.3390/cancers16112018.
8
Current Status and Future Perspectives of Antibody-Drug Conjugates in Hormone Receptor-Positive Breast Cancer.激素受体阳性乳腺癌中抗体药物偶联物的现状与未来展望
Cancers (Basel). 2024 May 8;16(10):1801. doi: 10.3390/cancers16101801.
9
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer.抗 HER2 药物治疗晚期 HER2 阳性乳腺癌。
Curr Treat Options Oncol. 2023 Nov;24(11):1633-1650. doi: 10.1007/s11864-023-01137-5. Epub 2023 Oct 25.
10
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).曲妥珠单抗德鲁替康治疗HER2阳性乳腺癌伴脑转移和/或软脑膜疾病患者（ROSET-BM）。
NPJ Breast Cancer. 2023 Oct 11;9(1):82. doi: 10.1038/s41523-023-00584-5.
Zotero 插件